Clinical Trials Logo
  1. Home
  2. Cancer of Stomach
  3. NCT00164892

Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial

Cancer of Stomach Clinical Trial

Official title:
Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial

Clinical Trial Summary

The purpose of this study is to investigate the efficacy of selective COX-II inhibitor in patients with curative resection performed for locally advanced stomach cancer.

Clinical Trial Description

Cyclo-oxygenase (COX) is a family of enzymes regulating the conversion of arachidonic acid to prostaglandins. COX-II is an inducible enzyme, which may be upregulated when there are stimuli such as inflammation or hypergastrinaemia. Despite radical surgery, patients with stomach cancer of advanced stages often have a poor prognosis. Reported survival in those with diseases of stage IIIa or above is less than 40%. Methods to improve patients outcome have been explored for decades with little success. In the light of current understanding on the relation between COX-II and stomach cancer, selective COX-II inhibitor may be used as a novel adjuvant therapy after gastrectomy to prevent recurrence of gastric carcinoma. The advantages of COX-II inhibitors are being relatively non-toxic with minimal side effect. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00164892
Study type Interventional
Source Chinese University of Hong Kong
Contact
Status Active, not recruiting
Phase Phase 3
Start date October 2004
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT00164918 - Role of Routine Nasogastric Decompression After Subtotal Gastrectomy Phase 3
Completed NCT00201747 - Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer Phase 2
Completed NCT05088304 - GLIM-defined Malnutrition Criteria for Postoperative Outcomes in Patients With Esophagogastric Cancer
Active, not recruiting NCT00165048 - Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial Phase 3
Recruiting NCT05179824 - Tempus Priority Study: A Pan-tumor Observational Study
Recruiting NCT03129139 - A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT03468712 - Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers N/A
Recruiting NCT03301493 - Genomic Testing and Resulting Medical Decisions
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Completed NCT01614522 - A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2 Phase 2
Completed NCT02374255 - Improving Goals of Care Discussion in Advanced Cancer Patients N/A
Recruiting NCT05804331 - The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
Active, not recruiting NCT03775525 - Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer Phase 1
Recruiting NCT04270890 - Investigation of an Abdominal Compression Device N/A
Recruiting NCT02486601 - NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma Phase 2
Completed NCT03541629 - Audit of the Spanish EURECCA Esophagogastric Cancer Registry
Completed NCT03102229 - Real-time Activity Monitoring to Prevent Admissions During RadioTherapy N/A
Not yet recruiting NCT05747482 - Omentectomy vs Omental Preservation in Resectable Cancer N/A
Completed NCT05688761 - Nordic Gastric and Esophageal Tumor Study
Completed NCT03719716 - Early Support in Primary Care for People Starting Treatment for Cancer N/A